MBX

49.5507.23%
ET

Edward T. Mathers

Independent Director

Mr. Edward T. Mathers, also known as Ed, B.Sc., is Director of Allergan GI Corp. from March 2013. He joined the Allergan GI Corp. in March 2013. He is Member of Board of Directors of Amplyx Pharmaceuticals, Inc. He is Independent Non-Employee Director of OnKure Therapeutics, Inc. from October 4, 2024. He is Director of Ziarco, Inc. He is Independent Director of Trevi Therapeutics, Inc. from July 20, 2017. He joined the Trevi Therapeutics, Inc. on July 20, 2017. He is Director of Rhythm Holding Company, LLC from March 2013. He joined the Rhythm Holding Company, LLC in March 2013. He is Director of Envisia Therapeutics Inc. He is Independent Director of Synlogic, Inc. from October 2012. He joined the Synlogic, Inc. in October 2012. He is Director of Splice Bio from February 16, 2022. He is Director of Cardurion Pharmaceuticals, Inc. from July 2024. He was Independent Director of Senti Biosciences Holdings, Inc. from July 2016 until October 27, 2026. He was Director of Senti Biosciences Holdings, Inc. from 2016. He is Board Member of Inversago Pharma Inc. from October 2022. He is Independent Director of MBX Biosciences, Inc. from July 2020. He is Director of Curzion Pharmaceuticals, Inc. He is Director of Shape Therapeutics Inc. He is Independent Director of Affinia Therapeutics, Inc. from March 2020. He is Director of Code Biotherapeutics, Inc. from April 2021. He joined the Code Biotherapeutics, Inc. in April 2021. He is Partner of NEA Management Company LLC. He joined the NEA Management Company LLC in 2008. He is Partner of New Enterprise Associates, Inc. He joined the New Enterprise Associates, Inc. on August 26, 2008. He focuses on Seed/Early, Growth, Healthcare, US. He was General Partner of New Enterprise Associates, Inc. from October 28, 2019. He was Partner of New Enterprise Associates, Inc. from August 26, 2008 to October 27, 2019. He was Executive Officer of Ortho Pharmaceutical Corporation. He was Executive Vice President of Corporate Development & Venture of MedImmune, LLC. He joined the MedImmune, LLC on February 22, 2005. He was Vice President of Marketing, Corporate Licensing and Acquisitions of Nektar Therapeutics. He was Executive Officer of GSK plc. He was Non-Employee Director of Mirna Therapeutics, Inc. He joined the Mirna Therapeutics, Inc. in October 2012. He was Director of Intarcia Therapeutics, Inc. He was Independent Chairman of the Board of Ra Pharmaceuticals, Inc. until April 2020. He was employed at Ra Pharmaceuticals, Inc. until April 2020. He was Director of Plexxikon Inc. He was Director of Kémia, Inc. He was Director of Liquidia Corporation from July 2009 to May 09, 2019. He was employed at Liquidia Corporation until May 09, 2019. He was Director of Satori Pharmaceuticals Incorporated. He was Member of Board of Directors of Lumena Pharmaceuticals, Inc. from March 2014. He joined the Lumena Pharmaceuticals, Inc. in March 2014. He was Independent Director of ObsEva SA from February 2016 to 2023. He was employed at ObsEva SA from February 2016 to 2023. He was Director of Lumos Pharma, Inc. from February 2014 to March 2020. He was employed at Lumos Pharma, Inc. from February 04, 2014 to March 2020. He was Independent Director of Reneo Pharmaceuticals, Inc. from December 2017. He was Lead Independent Director of Rhythm Pharmaceuticals, Inc. from December 2020 to April 2026. He was Independent Director of Rhythm Pharmaceuticals, Inc. from March 2013 to December 2020. He was employed at Rhythm Pharmaceuticals, Inc. until April 2026. He was Executive Vice President of Corporate Development and Venture of MedImmune Ventures, Inc. He was Independent Director of Akouos, Inc. from October 2017 to December 01, 2022. He was employed at Akouos, Inc. until December 01, 2022. He was Independent Director of Inozyme Pharma, Inc. from January 2017 to July 1, 2025. He was employed at Inozyme Pharma, Inc. until July 1, 2025. He was Independent Director of Mirum Pharmaceuticals, Inc. from November 2018 to September 01, 2022. He was employed at Mirum Pharmaceuticals, Inc. from November 2018 to September 01, 2022. He has B.S. in Chemistry from North Carolina State University.

Positions